PPHM Opinions 08/29/2014 08:30:54 $PPHM
Krak, I asked IR about incr. Audit Fees ($336k/’13 => $522k/’14), and they responded, “This is tied to the increased number of filings including those tied to the preferred offering and quarterly dividends.”
= = = = = = = = = = = = = =
Proxy Filed 8-28-14 (Def14A): http://tinyurl.com/kvnxgwg
…SHM 10-16-14/Thu. 10:30amPT, Irvine Marriott, Irvine, CA
…PPHM’s indep. registered public accounting firm: Ernst & Young LLP
…As of 8-22-14, there were 179,226,424 shares o/s, +16,966 since 7-7-14, +355,260 since 4-30-14.
2014 Oncology Drugs in the Pipeline
Sorafenib (Nexavar; Bayer, Onyx), a multikinase inhibitor, remains the only standard systemic therapy for advanced hepatocellular carcinoma (HCC). However, the survival benefit is modest and no second-line therapy currently exists. Therefore, systemic therapy for advanced HCC is an evolving field.
A novel potential target for HCC is phosphatidylserine (PS), a potent immunosuppressive agent located in the inner aspect of the plasma membrane. Exposure of the PS to the outer plasma membrane leaflet and its subsequent interaction with PS receptors on immune cells leads to immunosuppression and tumor progression. External PS is abundant in the tumor environment and is markedly enhanced by therapy (eg, radiation/chemotherapy).
Several pre-clinical trials have demonstrated that antibody-mediated PS blockade leads to increased cytotoxic T-cell immunity and decreased immunosuppression. This has led to the use of bavituximab (Peregrine Pharmaceuticals), a chimeric PS targeting antibody, in several phase 2 clinical trials.
The drug is being studied in HCC by Adam Yopp, MD, assistant professor of surgery at UT Southwestern in Dallas. The combination of bavituximab with sorafenib could be a promising option for patients with advanced HCC as it targets immune checkpoints at different levels, potentially leading to a robust antitumor immunity that is a very exciting field currently. This has the potential to significantly impact clinical outcomes for these patients, while demonstrating a very favorable adverse-effect profile. Accrual is proceeding on target and results are expected in 2015.
Sarbajit Mukherjee, MD, and Renuka Iyer, MD
Roswell Park Cancer Institute
http://www.healio.com/hematology-oncology/new...e-pipeline
PPHM Stock Message Board http://investorshangout.com/Peregrine-Pharmac...PHM-55152/
I guess its like old war wounds. At the end if this road Bavi will IMO win!
Just one hurdle at a time.
N
We've had a few of those from pphm in the past and they come without ANESTHESIA.
I second that notion!.... Everybody should just wook it up some day!
Thanks D.
CP...an inevitable truth is that credit must be earned before it can be lost. It can be earned again.
This is true of people and companies.
IMHO.....It is time to give credit where credit is due.
wook
Lmao. What a classic post !
N
Stone, I had the same thought!
AtonewithPPHM
Nice post Wookster !
To all aboard enjoy, be safe, and go North with pphm.
Feel good J.
D
Bio now that we've avoided a group colonoscopy lets hope the rest of your PPHM prediction comes true. Especially a possible BTD for breast.
Thanks, CP.
I wonder if the pr next week will be more than just the quarterly conference call schedule (last year it was Sept. 9). Something on the breast cancer meeting would be nice.
(7)
Krak, I asked IR about incr. Audit Fees ($336k/’13 => $522k/’14), and they responded, “This is tied to the increased number of filings including those tied to the preferred offering and quarterly dividends.”
= = = = = = = = = = = = = =
Proxy Filed 8-28-14 (Def14A): http://tinyurl.com/kvnxgwg
…SHM 10-16-14/Thu. 10:30amPT, Irvine Marriott, Irvine, CA
…PPHM’s indep. registered public accounting firm: Ernst & Young LLP
…As of 8-22-14, there were 179,226,424 shares o/s, +16,966 since 7-7-14, +355,260 since 4-30-14.
2014 Oncology Drugs in the Pipeline
Sorafenib (Nexavar; Bayer, Onyx), a multikinase inhibitor, remains the only standard systemic therapy for advanced hepatocellular carcinoma (HCC). However, the survival benefit is modest and no second-line therapy currently exists. Therefore, systemic therapy for advanced HCC is an evolving field.
A novel potential target for HCC is phosphatidylserine (PS), a potent immunosuppressive agent located in the inner aspect of the plasma membrane. Exposure of the PS to the outer plasma membrane leaflet and its subsequent interaction with PS receptors on immune cells leads to immunosuppression and tumor progression. External PS is abundant in the tumor environment and is markedly enhanced by therapy (eg, radiation/chemotherapy).
Several pre-clinical trials have demonstrated that antibody-mediated PS blockade leads to increased cytotoxic T-cell immunity and decreased immunosuppression. This has led to the use of bavituximab (Peregrine Pharmaceuticals), a chimeric PS targeting antibody, in several phase 2 clinical trials.
The drug is being studied in HCC by Adam Yopp, MD, assistant professor of surgery at UT Southwestern in Dallas. The combination of bavituximab with sorafenib could be a promising option for patients with advanced HCC as it targets immune checkpoints at different levels, potentially leading to a robust antitumor immunity that is a very exciting field currently. This has the potential to significantly impact clinical outcomes for these patients, while demonstrating a very favorable adverse-effect profile. Accrual is proceeding on target and results are expected in 2015.
Sarbajit Mukherjee, MD, and Renuka Iyer, MD
Roswell Park Cancer Institute
http://www.healio.com/hematology-oncology/new...e-pipeline
PPHM Stock Message Board http://investorshangout.com/Peregrine-Pharmac...PHM-55152/
I guess its like old war wounds. At the end if this road Bavi will IMO win!
Just one hurdle at a time.
N
We've had a few of those from pphm in the past and they come without ANESTHESIA.
I second that notion!.... Everybody should just wook it up some day!
Thanks D.
CP...an inevitable truth is that credit must be earned before it can be lost. It can be earned again.
This is true of people and companies.
IMHO.....It is time to give credit where credit is due.
wook
Lmao. What a classic post !
N
Stone, I had the same thought!
AtonewithPPHM
Nice post Wookster !
To all aboard enjoy, be safe, and go North with pphm.
Feel good J.
D
Bio now that we've avoided a group colonoscopy lets hope the rest of your PPHM prediction comes true. Especially a possible BTD for breast.
Thanks, CP.
I wonder if the pr next week will be more than just the quarterly conference call schedule (last year it was Sept. 9). Something on the breast cancer meeting would be nice.
(7)
